Business Context and Reporting Period
This Form 8-K was filed by Glucotrack, Inc. on May 26, 2023, regarding a corporate event occurring on the same date. The Company is incorporated in Delaware and maintains its principal executive offices in Or Yehuda, Israel.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
The Company received a notification from Nasdaq stating it no longer complies with Rule 5550(a)(2) of the Nasdaq Listing Rules. This rule requires listed securities to maintain a minimum bid price of $1.00 per share. The non-compliance is based on the closing bid price for the last 30 consecutive business days.
Outlook, Risks, and Contingencies
- Compliance Period: Nasdaq has granted the Company a 180-calendar-day period to regain compliance.
- Remediation Path: Under Rule 5810(c)(3)(C), the Company must achieve a closing bid price of at least $1.00 for a minimum of ten consecutive business days within the 180-day window to receive written confirmation of compliance.
- Delisting Risk: If the Company fails to regain compliance by the 180th day, it may face delisting, though it may be eligible for additional time to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of Glucotrack, Inc. stock to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward achieving ten consecutive days of trading at or above $1.00 within the 180-day window.
- Review subsequent filings for any updates on the compliance status or potential delisting proceedings.